Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 107, 52-56

VALHUDES: A Protocol for Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self-Samples and Urine Samples

Affiliations

VALHUDES: A Protocol for Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self-Samples and Urine Samples

M Arbyn et al. J Clin Virol.

Abstract

Back ground: Systematic reviews have concluded that hrHPV DNA testing using target-amplification tests is as accurate on vaginal self-samples as on clinician-taken specimens for the detection of cervical precancer. However, insufficient evidence is available for specific HPV assay/self-sample device combinations.

Objectives: The VALHUDES protocol is designed as a diagnostic test accuracy study that aims to compare the clinical sensitivity and specificity of particular hrHPV assay(s) on vaginal self-samples and first-void-urine, collected in agreement with standardized protocols, with hrHPV testing on matched clinician-taken samples.

Study design: Five hundred enrolled women referred to a colposcopy clinic are invited to collect a first-void urine sample and one or more vaginal self-samples with particular devices before collection of a cervical sample by a clinician. Sample sets are subsequently analysed in a laboratory accredited for HPV testing. Disease verification for all enrolled patients is provided by colposcopy combined with histological assessment of biopsies.

Results: A first VALHUDES study has started in Belgium in December 2017 with enrolment from four colposcopy centres. The following assays are foreseen to be evaluated: RealTime High Risk HPV assay (Abbott), cobas-4800 and -6800 (Roche), Onclarity (BD), Xpert HPV (Cepheid) and Anyplex II HPV HR (Seegene).

Conclusion: Given empirical evidence that the relative accuracy of HPV-testing on self- vs clinician-samples is robust across clinical settings, the VALHUDES protocol offers a framework for validation of HPV assay/self-sample device combinations that can be translated to a primary screening setting.

Trial registration: ClinicalTrials.gov NCT03064087.

Keywords: Cervical cancer; Diagnostic test accuracy; Screening; Self-sampling; Test validation; Urine collection; VALHUDES.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

Publication types

MeSH terms

Associated data

LinkOut - more resources

Feedback